February 20, 2025 | Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH
Joel Neal, MD, PhD, and Sarah Goldberg, MD, MPH, examine treatment considerations for patients with high-risk EGFR-mutated NSCLC, including those with CNS metastases or co-occurring genomic alterations. Neal reviews how disease burden and aggressive clinical features may influence the choice of combination therapy. Goldberg highlights the need for individualized approaches that balance response depth with tolerability in vulnerable populations.
Related Posts
Factors Driving Frontline Treatment Selection in EGFR-Mutated NSCLC
The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management
AE Management With Subcutaneous Amivantamab in EGFR-Mutated NSCLC
How Frontline Therapy Affects Sequencing Considerations in EGFR-Mutated NSCLC
